Update on the use of aromatase inhibitors in early-stage breast cancer

Breast Cancer Research

Volumn 11, Issue 5, 2009, Pages

  Kesisis, Georgios ^a   Makris, Andreas ^a   Miles, David ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ARTHRALGIA; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPAREUNIA; EARLY CANCER; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FOLLOW UP; FRACTURE; HEART INFARCTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; JOINT STIFFNESS; LIBIDO DISORDER; LONG TERM CARE; LUNG EMBOLISM; MENSTRUAL IRREGULARITY; META ANALYSIS (TOPIC); MONOTHERAPY; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PRACTICE GUIDELINE; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UTERUS MYOMA; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; BREAST TUMOR; CANCER STAGING; ENZYMOLOGY; FEMALE; PATHOLOGY;

AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING;

EID: 77449116879     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2410     Document Type: Review

References (81)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
2. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000, 18:3748-3757.
3. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicentre randomized trial. J Clin Oncol 2000, 18:3758-3767.
4. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, . Arimidex Writing Committee; Investigators Committee Members Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis. Cancer 2001, 92:2247-2258. 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y, 11745278, Arimidex Writing Committee; Investigators Committee Members.
5. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A. Phase III Study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21:2101-2109. 10.1200/JCO.2003.04.194, 12775735.
6. Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lonning PE. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997, 3:1101-1108.
7. di Salle E, Ornati G, Giudici D, Lassus M, Evans TR, Coombes RC. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1992, 43:137-143. 10.1016/0960-0760(92)90198-R, 1525055.
8. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629. 10.1200/JCO.2005.09.121, 15545664.
9. NICE Final Appraisal Determination - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer, August 2006. , http://www.nice.org.uk/nicemedia/pdf/breast_cancer_hormonal_FAD.pdf
10. Chlebowski RT. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. Breast Cancer Res Treat 2008, 112:25-34. 10.1007/s10549-008-0237-5, 19101792.
11. Seruga B, Tannock IF. Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol 2009, 27:840-842. 10.1200/JCO.2008.19.5594, 19139426.
12. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, . ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139. 10.1016/S0140-6736(02)09088-8, 12090977, ATAC Trialists' Group.
13. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53. 10.1016/S1470-2045(07)70385-6, 18083636, Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group.
14. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. Breast International Group (BIG) 1-98 Collaborative Group A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. 10.1056/NEJMoa052258, 16382061, Breast International Group (BIG) 1-98 Collaborative Group.
15. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492. 10.1200/JCO.2006.08.8617, 17200148.
16. Mouridsen HT, Giobbie-Hurder A, Mauriac L, Paridaens R, Colleoni M, Thuerlimann B, Forbes JF, Gelber RD, Wardley A, Smith I, Price KN, Coates A, Goldhirsch A, . BIG I-98 Collaborative and the International Breast Cancer Study Group BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract 13]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14 December 2008; San Antonio, TX BIG I-98 Collaborative and the International Breast Cancer Study Group., http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_553&terms=
17. Ingle JN, Dowsett M, Cuzick J, Davies C. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14 December 2008; San Antonio, TX , http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_465&terms=
18. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Velde C, . Intergroup Exemestane Study A randomized trial of examestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092. 10.1056/NEJMoa040331, 15014181, Intergroup Exemestane Study.
19. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007, 369:559-570. 10.1016/S0140-6736(07)60200-1, 17307102.
20. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G. Improved overall survival in post-menopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007, 25:2664-2670. 10.1200/JCO.2006.08.8054, 17563395.
21. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006, 7:991-996. 10.1016/S1470-2045(06)70948-2, 17138220.
22. Jakesz R, Gnant M, Griel R, Tausch C, Samonigg H, Kwasny W, Kubista E, Stierer M, Luschin G, Rüecklinger E, Mittlböck M. Tamoxifen and anastrozole as a sequencing strategy in post-menopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14 December 2008; San Antonio, TX , http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_759&terms=
23. Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J-M, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett JMS, Velde CJH. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer [abstract 15]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; 10-14 December 2008; San Antonio, TX , http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_55&terms=
24. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802. 10.1056/NEJMoa032312, 14551341.
25. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomised trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005, 97:1262-1271.
26. Goss PE, Ingle JN, Palmer MJ, Shepherd LE. Updated analysis of NCIC MA17 (letrozole versus placebo to letrozole versus placebo) post unblinding [abstract 16]. Breast Cancer Res Treat 2005, 94:S1. 10.1007/s10549-005-1234-6, 16374922.
27. Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis 1993, 4:935-942.
28. Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 1992, 152:317-320. 10.1001/archinte.152.2.317, 1739360.
29. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388. 10.1093/jnci/90.18.1371, 9747868.
30. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006, 7:633-643. 10.1016/S1470-2045(06)70767-7, 16887480, Arimidex, Tamoxifen, Alone or in Combination Trialists' Group.
31. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, . ABCSG and the GABG Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462. 10.1016/S0140-6736(05)67059-6, 16084253, ABCSG and the GABG.
32. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, . ATAC Trialists' Group Quality of life of postmenopausal women in the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006, 100:273-284. 10.1007/s10549-006-9260-6, 16944295, ATAC Trialists' Group.
33. Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in post-menopausal women with primary breast cancer. J Clin Oncol 2006, 24:910-917. 10.1200/JCO.2005.03.3654, 16484701.
34. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal symptoms in young breast cancer survivors. Ann Oncol 2006, 17:1777-1782. 10.1093/annonc/mdl299, 16971671.
35. Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP, . WHEL Study Group Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 2008, 108:421-426. 10.1007/s10549-007-9612-x, 2575100, 17541741, WHEL Study Group.
36. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992, 326:852-856.
37. Coleman RE, . on behalf of the ATAC Trialists' Group Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006, 24(June 20 Suppl):511. on behalf of the ATAC Trialists' Group.
38. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005, 23:5126-5137. 10.1200/JCO.2005.07.097, 15983390.
39. McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007, 43:2523-2531. 10.1016/j.ejca.2007.08.029, 18029171.
40. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, . ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62. 10.1016/S0140-6736(05)74803-0, 15639680, ATAC Trialists' Group.
41. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (, . Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98:1802-1810. 10.1002/cncr.11745, 14584060, Tamoxifen Alone or in Combination) Trialists' Group.
42. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in post-menopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836. 10.1200/JCO.2005.05.3744, 17159193.
43. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, . Austrian Breast and Colorectal Cancer Study Group Zoledronic acid prevents cancer treatment-induced bone loss in pre-menopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828. 10.1200/JCO.2005.02.7102, 17159195, Austrian Breast and Colorectal Cancer Study Group.
44. Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008, 112:1001-1010. 10.1002/cncr.23259, 18205185.
45. Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007, 25:3797-3799. 10.1200/JCO.2007.11.9529, 17761968.
46. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25:3877-3883. 10.1200/JCO.2007.10.7573, 17761973.
47. Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008, 26:3147-3152. 10.1200/JCO.2007.15.4005, 18474874.
48. Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues 2001, 11:95-102. 10.1016/S1049-3867(01)00075-5, 11275512.
49. Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 2005, 103:1114-1121. 10.1002/cncr.20900, 15712362.
50. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 1995, 311:977-980. 2550987, 7580638.
51. Nabholtz J-M, Gligorov J. Comparison of cardiovascular safety profiles of aromatase inhibitors. Eur J Cancer Suppl 2005, 3:96.
52. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Jakesz R. Switching from adjuvant tamoxifen to anastrozole in post-menopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG Trial 8 and the ITA trial [abstract 18]. Breast Cancer Res Treat 2005, 94:S1. 10.1007/s10549-005-1234-6, 16374922.
53. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004, 22:4261-4271. 10.1200/JCO.2004.08.029, 15514369.
54. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005, 23:6931-6940. 10.1200/JCO.2005.11.181, 16157934.
55. Swedish Breast Cancer Cooperative Group Randomized trial of two versus five years of adjuvant tamoxifen for post-menopausal early stage breast cancer. J Natl Cancer Inst 1996, 88:1543-1549. 10.1093/jnci/88.21.1543, 8901852, Swedish Breast Cancer Cooperative Group.
56. Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005, 97:412-413.
57. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
58. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
59. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2d6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005, 5:6-13. 10.1038/sj.tpj.6500285, 15492763.
60. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotrans-formation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005, 23:9312-9318. 10.1200/JCO.2005.03.3266, 16361630.
61. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009, 9:576-586. 10.1038/nrc2683, 19629072.
62. Aubert RE, Stanek EJ, Yao J, Teagarden JR, Subar M, Epstein RS, Skaar TC, Desta Z, Flockhart DA. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 2009, 27:18s., http://meeting.ascopubs.org/cgi/content/abstract/27/18S/CRA508
63. Dezentje V, Van Blijderveen NJ, Gelderblom H. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: a pharmacoepidemiologic study. J Clin Oncol 2009, 27:18s.
64. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008, 100:642-648. 10.1093/jnci/djn100, 18445827.
65. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G, . IMPACT Trialists Group Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23:5108-5116. 10.1200/JCO.2005.04.005, 15998903, IMPACT Trialists Group.
66. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Relationship between quantitative estrogen receptor and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 2008, 26:1059-1065. 10.1200/JCO.2007.12.9437, 18227529.
67. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005, 23:7512-7517. 10.1200/JCO.2005.01.4829, 16234518.
68. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifenresistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992, 24:85-95. 10.1007/BF01961241, 8095168.
69. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999, 79:1220-1226. 10.1038/sj.bjc.6690196, 2362250, 10098763.
70. Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003, 21:1967-1972. 10.1200/JCO.2003.09.098, 12743150.
71. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006, 24:3019-3025. 10.1200/JCO.2005.04.3034, 16754938.
72. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G, . BIG 1-98 Collaborative and International Breast Cancer Study Groups BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008, 9:23-28. 10.1016/S1470-2045(07)70386-8, 18083065, BIG 1-98 Collaborative and International Breast Cancer Study Groups.
73. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A, . Breast International Group Trial 1-98 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008, 26:5569-5575. 10.1200/JCO.2008.17.0829, 18981464, Breast International Group Trial 1-98.
74. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17:818-826. 10.1093/annonc/mdl016, 16497822.
75. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001, 19:3808-3816.
76. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for node-negative breast cancer: updated findings. J Natl Cancer Inst 2001, 93:684-690. 10.1093/jnci/93.9.684, 11333290.
77. Stewart JH, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001, 93:456-462. 10.1093/jnci/93.6.456, 11259471.
78. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996, 88:1828-1833. 10.1093/jnci/88.24.1828, 8961972.
79. Peto R, Davies C, . on Behalf of the ATLAS Collaboration ATLAS (adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women -- preliminary results. Breast Cancer Res Treat 2007, 106(Suppl 1). on Behalf of the ATLAS Collaboration., http://www.abstracts2view.com/sabcs07/view.php?nu=SABCS07L_1167&terms=
80. Gray G, Rea DW, Handley K, Marshall A, Pritchard MG, Perry P, Earl HM, Poole CJ, Salman A, Lee M, . aTTom Collaborators aTTom (adjuvant Tamoxifen--To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results. J Clin Oncol 2008, 26. aTTom Collaborators., http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/513
81. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008, 34(Suppl 1):S3-18. 10.1016/j.ctrv.2008.03.007, 18515009.